Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Pegol

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    136 result(s) found for: Pegol. Displaying page 1 of 7.
    1  2  3  4  5  6  7  Next»
    EudraCT Number: 2006-002027-16 Sponsor Protocol Number: RPCG06B2433 Start Date*: 2006-12-12
    Sponsor Name:UCB AE
    Full Title: Certolizumab pegol 400 mg monthly in the treatment of adult Greek patients with moderate to severe Crohn’s Disease, who have been previously treated successfully with infliximab but who have subseq...
    Medical condition: Certolizumab pegol in the treatment of adult Greek patients with moderate to severe Crohn’s Disease, who have been previously treated successfully with infliximab but who have subsequently lost the...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2017-003788-36 Sponsor Protocol Number: NN7088-4410 Start Date*: 2018-03-12
    Sponsor Name:Novo Nordisk A/S
    Full Title: Safety and Efficacy of turoctocog alfa pegol (N8-GP) in Prophylaxis and Treatment of Bleeds in Previously N8-GP Treated Patients with Severe Haemophilia A
    Medical condition: Haemophilia A
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10018938 Haemophilia A (Factor VIII) LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male
    Trial protocol: LT (Completed) GB (GB - no longer in EU/EEA) PT (Completed) GR (Completed) NO (Completed) DK (Completed) HU (Completed) FR (Completed) NL (Completed) DE (Completed) ES (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-018027-33 Sponsor Protocol Number: RA0043 Start Date*: 2024-08-30
    Sponsor Name:UCB BIOSCIENCES GmbH
    Full Title: A multicenter, open-label study to assess the pharmacokinetics, safety and efficacy of certolizumab pegol in children and adolescents with moderately to severely active polyarticular-course juvenil...
    Medical condition: Juvenile Idiopathic Arthritis
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-002716-26 Sponsor Protocol Number: C87088 Start Date*: 2008-01-22
    Sponsor Name:UCB Celltech
    Full Title: A phase IIIb, multinational, open-label, follow-on trial to C87085 designed to assess the long-term safety of certolizumab pegol, a pegylated Fab' fragment of a humanized anti TNF alpha monoclonal ...
    Medical condition: Crohn's disease
    Disease: Version SOC Term Classification Code Term Level
    16.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FI (Prematurely Ended) HU (Completed) LV (Completed) EE (Completed) IT (Completed) CZ (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-000830-38 Sponsor Protocol Number: C87080 Start Date*: 2008-10-07
    Sponsor Name:UCB Pharma S.A.
    Full Title: A Phase IIIB, multi-centre open label, follow-up study to evaluate the safety and efficacy of certolizumab pegol administered concomitantly with DMARDs in subjects with active rheumatoid arthriti...
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) IT (Completed) AT (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-005025-20 Sponsor Protocol Number: CR0012 Start Date*: 2018-03-21
    Sponsor Name:UCB Biosciences, Inc.
    Full Title: An open-label, multicenter study to assess the safety of certolizumab pegol in children and adolescents with active Crohn's Disease who completed C87035 or who were terminated from C87035 when the ...
    Medical condition: Crohn´s Disease
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-003657-15 Sponsor Protocol Number: SNOXA12C601 Start Date*: 2017-03-09
    Sponsor Name:NOXXON Pharma AG
    Full Title: A Two-Part, Open-Label Phase 1/2 Study to Evaluate Pharmacodynamic Effects and Safety of Olaptesed Pegol Monotherapy and Safety and Efficacy of Olaptesed Pegol / Pembrolizumab Combination Therapy i...
    Medical condition: Colorectal cancer with liver metastases Pancreatic cancer with liver metastases
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-002326-63 Sponsor Protocol Number: CDP870-050 Start Date*: 2005-09-21
    Sponsor Name:UCB Celltech
    Full Title: A Phase III Multi–center, Double–blind, Placebo–controlled, Parallel Group 24–Week Study to Assess the Efficacy and Safety of Two Dose Regimens of Liquid Certolizumab Pegol as Additional Medication...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    10039073
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) SK (Completed) CZ (Completed) EE (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2022-002860-59 Sponsor Protocol Number: ISEE2009 Start Date*: 2022-12-08
    Sponsor Name:IVERIC bio, Inc.
    Full Title: An Open-label Extension (OLE) Phase 3 Trial to Assess the Safety of Intravitreal Administration of avacincaptad pegol (Complement C5 Inhibitor) in Patients with Geographic Atrophy Who Previously Co...
    Medical condition: geographic atrophy
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10063947 Geographic atrophy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) HU (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) CZ (Trial now transitioned) BE (Trial now transitioned) AT (Trial now transitioned) LV (Trial now transitioned) HR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-003409-83 Sponsor Protocol Number: SL0046 Start Date*: Information not available in EudraCT
    Sponsor Name:UCB Biopharma SRL
    Full Title: A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of Dapirolizumab Pegol Treatment in Study Participants With Systemic Lupus Erythematosus
    Medical condition: Systemic lupus erythematosus
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned) ES (Ongoing) BG (Trial now transitioned) DE (Trial now transitioned) HU (Trial now transitioned) BE (Trial now transitioned) CZ (Trial now transitioned) GR (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) AT (Prematurely Ended) DK (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-003977-25 Sponsor Protocol Number: C87043 Start Date*: 2007-01-31
    Sponsor Name:UCB S.A
    Full Title: A phase III B multicentre open label 54 weeks clinical trial evaluating certolizumab pegol, a PEGylated Fab fragment of humanized antibody to tumor necrosis factor alpha (TNF alpha) on endoscopic a...
    Medical condition: Crohn's disease
    Disease: Version SOC Term Classification Code Term Level
    8.1 10011401 Crohn's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-000337-13 Sponsor Protocol Number: PreCePra Start Date*: 2013-05-13
    Sponsor Name:Universitätsklinikum Erlangen
    Full Title: Prediction of response to Certolizumab Pegol treatment by functional MRI of the brain. A multi-center, randomized double-blind controlled study Prediction of response to Certolizumab-Pegol in RA (P...
    Medical condition: Patients with active Rheumatoid Artrhitis (DAS28 > 3.2) despite DMARD therapy
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2005-002629-30 Sponsor Protocol Number: CDP870-051 Start Date*: 2006-01-30
    Sponsor Name:UCB Inc
    Full Title: A Phase III Multi-center, Open-label, Follow-up Study, to Assess the Safety and Efficacy of Liquid Certolizumab Pegol as Additional Medication to Methotrexate, in the Treatment of Signs and Symptom...
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    10039073
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) SK (Completed) CZ (Completed) EE (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2021-004947-25 Sponsor Protocol Number: NN7999-4670 Start Date*: 2023-07-12
    Sponsor Name:Novo Nordisk A/S
    Full Title: A multi-centre, open-label trial evaluating efficacy, safety and pharmacokinetics of nonacog beta pegol when used for treatment and prophylaxis of bleeding episodes in Chinese patients with haemo...
    Medical condition: Haemophilia B
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10018939 Haemophilia B (Factor IX) LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-004457-40 Sponsor Protocol Number: SL0023 Start Date*: 2016-09-19
    Sponsor Name:UCB Biopharma SPRL
    Full Title: A MULTI-CENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, DOSE RANGING STUDY FOLLOWED BY AN OBSERVATIONAL PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN SU...
    Medical condition: SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10040967 SLE LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) RO (Completed) HU (Completed) BG (Completed) ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2014-004399-42 Sponsor Protocol Number: C87037 Start Date*: 2015-03-05
    Sponsor Name:UCB Japan Co., Ltd.
    Full Title: A Phase II, Multi-center, Double-blind, Placebo-controlled, Parallel-group, Dose-response Study to Assess the Safety and Efficacy of CDP870/Certolizumab Pegol, Dosed Subcutaneously in Patients With...
    Medical condition: Crohn’s Disease
    Disease: Version SOC Term Classification Code Term Level
    17.1 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-001913-41 Sponsor Protocol Number: C87085 Start Date*: 2007-12-12
    Sponsor Name:UCB Celltech
    Full Title: A phase IIIb, multinational, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of certolizumab pegol, a pegylated Fab' fragment of a humanized anti-TNF-alpha mono...
    Medical condition: Crohn`s disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011401 Crohn's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended) HU (Completed) LV (Completed) BE (Completed) EE (Completed) IT (Completed) DE (Completed) CZ (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2015-005327-63 Sponsor Protocol Number: NN7088-4033 Start Date*: 2016-12-08
    Sponsor Name:Novo Nordisk A/S
    Full Title: A multi-centre, comparative, double blind, randomised cross-over trial investigating single dose pharmacokinetics and safety of turoctocog alfa pegol from the pivotal process and turoctocog alfa pe...
    Medical condition: Haemophilia A
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004850 10018938 Haemophilia A (Factor VIII) LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male
    Trial protocol: NL (Completed) DK (Completed) DE (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-003513-28 Sponsor Protocol Number: PS0005 Start Date*: 2015-03-27
    Sponsor Name:UCB Biopharma, SPRL
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Parallel-group Study Followed by a Dose-blind Period and Open Label Follow-up to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects...
    Medical condition: Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2018-004064-62 Sponsor Protocol Number: SNOXA12C401 Start Date*: 2019-05-07
    Sponsor Name:TME Pharma AG
    Full Title: Single-arm, dose-escalation Phase 1/2 Study of olaptesed pegol (NOX-A12) in combination with irradiation in inoperable or partially resected first-line glioblastoma patients with unmethylated MGMT ...
    Medical condition: glioblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jul 04 20:05:21 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA